# Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)

> **NCT05393037** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 313 (actual)

## Conditions studied

- Pneumococcal Disease

## Interventions

- **BIOLOGICAL:** V116
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** PCV15
- **BIOLOGICAL:** PPSV23
- **BIOLOGICAL:** PCV15 - Part B

## Key facts

- **NCT ID:** NCT05393037
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-13
- **Primary completion:** 2023-07-13
- **Final completion:** 2024-01-25
- **Target enrollment:** 313 (ACTUAL)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05393037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05393037, "Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT05393037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*